Cardiff Oncology Reports 72% ORR for Onvansertib in RAS-Mutant mCRC
Cardiff Oncology presented onvansertib clinical data at the Oppenheimer Healthcare Conference, showing a 72% objective response rate in RAS-mutant metastatic colorectal cancer patients. The company highlighted this result as a pivotal efficacy milestone, bolstering plans to advance its lead candidate into later-stage clinical studies.
1. Oppenheimer Healthcare Presentation
Cardiff Oncology showcased onvansertib data at the Oppenheimer Healthcare Conference, revealing a 72% objective response rate in patients with RAS-mutant metastatic colorectal cancer. The company emphasized this efficacy signal as a critical development milestone, supporting plans to push its lead oncology candidate into pivotal trials.
Related News
VBCH
Vanguard’s BondBuilder Suite Amasses $242M in Two Months, Fuels $70B ETF Segment
VBCH•
AMZN
Amazon MGM Invests $75M in Melania Documentary Despite Political Scrutiny
AMZN•
BA
NTSB: Boeing Extended MD-11 Inspection Interval 47% Before Deadly UPS Crash
BA•
VVOS
Vivos Therapeutics Q1 Revenue Up 70%, Gross Margin Rises to 60%
VVOS•
JAGX
Jaguar Health Q1 Revenue Jumps 816% to $20.3M on $19M License Deal
JAGX•
Sources
F